Digoxin and Senolysis in Heart Failure and Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT06240403

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06240403
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06240403. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-01 (anticipated); primary completion 2028-08-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Digoxin and Senolysis in Heart Failure and Diabetes Mellitus
Condition
Heart Failure, Systolic
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Digoxin 0.125 MG
Lead sponsor
University of Leeds (class: other)

Record details

Record id
cardio:ct-nct06240403
Content hash
10c0f0edbbea61dd6da9421d37d328086b6c6dcd96f3fbc133068a6794135aa8